Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

sipuleucel-T

- PMLiVE

Pfizer’s 2021 revenue predictions soar to $82bn

Strong third-quarter revenues of $24.1bn lifted by sales of its BioNTech-partnered COVID-19 vaccine Comirnaty see Pfizer raise its 2021 revenue guidance to $82bn

- PMLiVE

Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19

Results from the world’s first randomised, controlled COVID-19 vaccine booster trial show a third dose of Pfizer-BioNTech’s Comirnaty offers near-total protection from infection

- PMLiVE

NICE recommends Novartis’ Adakveo for sickle cell disease

The treatment for sickle cell disease is the first in more than 20 years

- PMLiVE

Positive data for Lyme disease booster vaccine

A booster shot of Valneva/Pfizer’s VLA15 vaccine candidate against tick-borne Lyme disease demonstrates a strong immune response

- PMLiVE

COVID-19 Pfizer/BioNTech booster approved by FDA and CDC

The plan to offer Americans a third, booster shot of the Pfizer/BioNTech COVID-19 vaccine has finally been waved through by the FDA and CDC

- PMLiVE

UK announces COVID boosters for a “bumpy winter” ahead

A single shot of Pfizer’s COVID-19 vaccine will be offered to 30 million people in the UK including those 50 or over and frontline health and social care workers

- PMLiVE

Pfizer starts RSV trial ahead of winter season

A vaccine against the common respiratory syncytial virus could be available soon, as Pfizer joins GSK and J&J in launching phase 3 trials

- PMLiVE

UK’s NICE recommends anti-cholesterol Leqvio for high-risk patients

The approval for the Novartis drug by the NHS gatekeeper could save 30,000 lives over 10 years

- PMLiVE

Pfizer/BioNTech file for FDA approval for COVID-19 booster jab

New data shows third dose boosts antibodies by more than three times

- PMLiVE

Pfizer to acquire Canadian immuno-oncology company Trillium in a deal worth $2.6bn

The deal will strengthen Pfizer’s oncology offering and follows an investment of $25m in Trillium made by Pfizer in January

- PMLiVE

NICE recommends Novartis’ Rydapt for advanced SM treatment

The twice-daily, oral drug improves overall survival of people with the rare blood disorder

- PMLiVE

UK’s NICE to revamp its processes to make access to medicines “fairer”

The health technology assessment body is running a consultation to make its processes “clear, transparent and predictable”

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links